Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial

Study limitation reported by the research below: “The ≥3 HRCAs subgroup did not appear to benefit, but exact numbers and CIs for this subgroup are not reported in the abstract.”